Texas Permanent School Fund Acquires 398 Shares of Sucampo Pharmaceuticals, Inc. (SCMP)
Texas Permanent School Fund raised its position in shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) by 2.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 18,319 shares of the biopharmaceutical company’s stock after buying an additional 398 shares during the period. Texas Permanent School Fund’s holdings in Sucampo Pharmaceuticals were worth $192,000 at the end of the most recent reporting period.
Other large investors have also made changes to their positions in the company. Louisiana State Employees Retirement System purchased a new stake in Sucampo Pharmaceuticals during the first quarter valued at $111,000. Karp Capital Management Corp purchased a new stake in Sucampo Pharmaceuticals during the first quarter valued at $119,000. First Citizens Bank & Trust Co. purchased a new stake in Sucampo Pharmaceuticals during the second quarter valued at $116,000. Capstone Asset Management Co. purchased a new stake in Sucampo Pharmaceuticals during the first quarter valued at $133,000. Finally, New York State Teachers Retirement System purchased a new stake in Sucampo Pharmaceuticals during the first quarter valued at $137,000. 55.44% of the stock is owned by institutional investors.
Sucampo Pharmaceuticals, Inc. (SCMP) opened at 11.50 on Thursday. The firm’s 50-day moving average price is $10.74 and its 200 day moving average price is $10.65. The firm’s market cap is $532.74 million. Sucampo Pharmaceuticals, Inc. has a 52 week low of $9.30 and a 52 week high of $17.55.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $0.06. Sucampo Pharmaceuticals had a positive return on equity of 56.58% and a negative net margin of 61.99%. The company had revenue of $59.90 million during the quarter, compared to analyst estimates of $56.44 million. During the same period in the prior year, the company earned $0.24 earnings per share. The firm’s revenue was up 15.3% on a year-over-year basis. Equities analysts forecast that Sucampo Pharmaceuticals, Inc. will post $1.02 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Texas Permanent School Fund Acquires 398 Shares of Sucampo Pharmaceuticals, Inc. (SCMP)” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/31/texas-permanent-school-fund-acquires-398-shares-of-sucampo-pharmaceuticals-inc-scmp.html.
Several research firms recently weighed in on SCMP. Zacks Investment Research raised shares of Sucampo Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 4th. ValuEngine raised shares of Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Maxim Group reaffirmed a “buy” rating and set a $23.00 price objective (up previously from $21.00) on shares of Sucampo Pharmaceuticals in a research report on Tuesday, August 8th. BidaskClub cut shares of Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 5th. Finally, Roth Capital set a $30.00 price objective on shares of Sucampo Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Three equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. Sucampo Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $17.33.
In other news, insider Jones W. Bryan purchased 4,700 shares of the company’s stock in a transaction that occurred on Friday, August 4th. The stock was bought at an average cost of $10.60 per share, with a total value of $49,820.00. Following the completion of the purchase, the insider now owns 4,700 shares in the company, valued at $49,820. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.13% of the stock is currently owned by corporate insiders.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Want to see what other hedge funds are holding SCMP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP).
Receive News & Stock Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.